Patent · US Active

Modified IL-13 polypeptides

US9512194B2 · kind B2 · utility

12Cited by

0References

7Claims

0Family size

Assignee

The Board of Trustees of the Leland Stanford Junior University · US

Inventors

Kenan Christopher Garcia · Menlo Park, US
Ignacio Moraga Gonzalez · Palo Alto, US

Key dates

Filing date	Jan 25, 2013
Grant date	Dec 6, 2016
Priority date	—
Expiry date	Sep 7, 2033

Classification

Technology area (CPC G)Physics
CPC primaryG09G2320/0247
WIPO fieldAudio-visual technology
WIPO sectorElectrical engineering

Abstract

Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13Rα2, relative to the native human IL-13 protein; (b) altered affinity for IL-13Rα1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4Rα relative to the native human IL-13 protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.